Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAgrima MianANAdrienne NedvedNGNatalie S. Grover

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reveals poor clinical outcomes post-progression of disease in large B-cell lymphoma, highlighting bispecific antibodies' limitations.

Key Points

  • Progression of disease occurred early after bispecific antibody treatment, with most patients not receiving subsequent therapies.
  • Among patients treated, those receiving chimeric antigen receptor T-cell therapy showed limited overall survival at 3.9 months.
  • Clinical outcomes were particularly challenging for patients who had completed initial therapy without achieving a complete response.
  • The findings suggest urgent need for continued trials of innovative therapies for relapsed or refractory large B-cell lymphoma patients.

Cite This Study

Mian et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d74ahttps://doi.org/10.1182/blood-2025-402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need2025
  2. 2Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations2025
  3. 3Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma2025
  4. 4Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma2025
  5. 5Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas2025